ACADIA PHARMACEUTICALS INC
ACAD
28 insider filings · Latest: Aug 5, 2026
Common Stock Transactions
| Txn Date | Accepted | Insider | Type | Shares | Avg Price | Value | Shares Owned | Filing |
|---|---|---|---|---|---|---|---|---|
| Nov 10, 2025 | Nov 10 10:59 PM | James M Daly | Proposed Sale | 30,000 | $22.37 | $671.0K | — | View → |
| Aug 18, 2025 | Aug 18 8:31 PM | Schneyer Mark C. | Proposed Sale | 22,000 | $25.33 | $557.3K | — | View → |
| Jun 4, 2025 | Jun 4 8:35 PM | LAURA BREGE | Proposed Sale | 14,446 | $21.78 | $314.6K | — | View → |
| May 16, 2025 | May 16 9:10 PM | Schneyer Mark C. | Proposed Sale | 2,000 | $17.60 | $35.2K | — | View → |
| May 16, 2025 | May 16 9:06 PM | Kihara James | Proposed Sale | 4,000 | $17.60 | $70.4K | — | View → |
| Mar 5, 2025 | Mar 6 5:17 PM | GAROFALO ELIZABETH A. | Proposed Sale | 4,919 | $18.23 | $89.7K | — | View → |
← Previous
Page 2 of 2
Stock Options & Derivatives
| Txn Date | Accepted | Insider | Type | Shares | Exercise Price | Shares Owned | Filing |
|---|---|---|---|---|---|---|---|
| Mar 24, 2026 | Mar 27 12:00 AM | Adams Catherine OwenDirector, Chief Executive Officer | Option Exercise | 23,509 | — | 70,530(D) | View → |
| Mar 24, 2026 | Mar 27 12:00 AM | Jennifer J RhodesEVP, CHIEF LEGAL OFFICER, SEC | Option Exercise | 7,515 | — | 22,547(D) | View → |
| Mar 24, 2026 | Mar 27 12:00 AM | Elizabeth H.Z. ThompsonEVP, Head of Research & Dev | Option Exercise | 6,715 | — | 20,146(D) | View → |
| Mar 25, 2026 | Mar 27 12:00 AM | James KiharaPRINCIPAL ACCOUNTING OFFICER | Option Exercise | 2,142 | — | 4,284(D) | View → |
| Mar 24, 2026 | Mar 27 12:00 AM | James KiharaPRINCIPAL ACCOUNTING OFFICER | Option Exercise | 1,627 | — | 4,883(D) | View → |
| Mar 25, 2026 | Mar 27 12:00 AM | Mark C. SchneyerEVP, CHIEF FINANCIAL OFFICER | Option Exercise | 6,178 | — | 12,358(D) | View → |
| Mar 24, 2026 | Mar 27 12:00 AM | Mark C. SchneyerEVP, CHIEF FINANCIAL OFFICER | Option Exercise | 8,138 | — | 24,414(D) | View → |
| Mar 3, 2026 | Mar 20 10:01 PM | Jonathan PooleDirector | Grant/Award | 17,275 | $22.50 | 2,010(D) | View → |
| Mar 6, 2026 | Mar 10 10:00 PM | James KiharaPRINCIPAL ACCOUNTING OFFICER | Grant/Award | 28,098 | $22.16 | 6,332(D) | View → |
| Mar 6, 2026 | Mar 10 10:00 PM | Jennifer J RhodesEVP, CHIEF LEGAL OFFICER, SEC | Grant/Award | 117,073 | $22.16 | 26,382(D) | View → |
| Mar 6, 2026 | Mar 10 10:00 PM | Mark C. SchneyerEVP, CHIEF FINANCIAL OFFICER | Grant/Award | 117,073 | $22.16 | 26,382(D) | View → |
| Mar 6, 2026 | Mar 10 10:00 PM | Thomas GarnerEVP, Chief Commercial Officer | Grant/Award | 126,440 | $22.16 | 28,493(D) | View → |
| Mar 6, 2026 | Mar 10 10:00 PM | Elizabeth H.Z. ThompsonEVP, Head of Research & Dev | Grant/Award | 131,122 | $22.16 | 29,548(D) | View → |
| Mar 6, 2026 | Mar 10 10:00 PM | Adams Catherine OwenDirector, Chief Executive Officer | Grant/Award | 339,514 | $22.16 | 76,509(D) | View → |
| Feb 6, 2026 | Feb 10 11:00 PM | Jennifer J RhodesEVP, CHIEF LEGAL OFFICER, SEC | Option Exercise | 12,944 | — | 12,945(D) | View → |
← Previous
Page 2 of 2